Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Name November 10, 2025 8:00 AM EST
Firm Contributors
Stephanie Lee Griffin – Chief Working Officer of Roivant Platforms
Matthew Gline – CEO & Director
Convention Name Contributors
David Risinger – Leerink Companions LLC, Analysis Division
Lut Ming Cheng – JPMorgan Chase & Co, Analysis Division
Samantha Semenkow – Citigroup Inc., Analysis Division
Yaron Werber – TD Cowen, Analysis Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Analysis Division
Corinne Jenkins – Goldman Sachs Group, Inc., Analysis Division
Yuchen Ding – Jefferies LLC, Analysis Division
Dominic Risso-Gill
Douglas Tsao – H.C. Wainwright & Co, LLC, Analysis Division
Hao Shen – Wells Fargo Securities, LLC, Analysis Division
Thomas Smith – Leerink Companions LLC, Analysis Division
Brandon Frith – Wolfe Analysis, LLC
Gaurav Maini – LifeSci Capital, LLC, Analysis Division
Presentation
Operator
Good day, and thanks for standing by. Welcome to the Roivant’s Second Quarter 2025 Earnings Name.
[Operator Instructions] Please observe that right this moment’s convention is being recorded. I’ll now hand the convention over to your first speaker Stephanie Lee. You could start.
Stephanie Lee Griffin
Chief Working Officer of Roivant Platforms
Good morning, and thanks for becoming a member of right this moment’s name to evaluate Roivant’s monetary outcomes for the second quarter ended September 30, 2025. I am Stephanie Lee with Roivant.
Presenting right this moment, we have now Matt Gline, CEO of Roivant. For these dialing in by way of convention name, yow will discover the slides being offered right this moment in addition to the press launch asserting these updates on our IR web site at www.investor.roivant.com. We’ll even be offering the present slide numbers as we current that will help you comply with alongside.
I might prefer to remind you that we’ll be ensuring forward-looking statements throughout right this moment’s presentation. We strongly encourage you to evaluate the data that we filed with the SEC for extra data relating to these forward-looking statements and associated dangers and uncertainties.
